Latest Sunitinib Stories

WAYNE, N.J., May 15, 2013 /PRNewswire/ -- Intended for U.S. Media Only -- Bayer HealthCare announced today that new data on the oncology portfolio, including Nexavar® (sorafenib) tablets, Stivarga® (regorafenib) tablets and the recently U.S. Food and Drug Administration (FDA) approved product Xofigo® (radium Ra 223 dichloride) injection will be presented at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO), May 31 - June 4, in Chicago, IL (USA). These data...

WAYNE, N.J., May 15, 2013 /PRNewswire/ -- Bayer HealthCare announced today that patient enrollment is underway for RESORCE (Regorafenib after Sorafenib in Patients with Hepatocellular Carcinoma), an international Phase III trial to evaluate the efficacy and safety of Stivarga(®) (regorafenib) tablets for the treatment of patients with hepatocellular carcinoma (HCC) who have progressed on Nexavar(®) (sorafenib) tablets, an anticancer medicine for the treatment of patients with...

A new blood test revealed more of the gene mutations that sustain certain digestive-tract tumors than did a DNA analysis of a traditional tumor biopsy, Dana-Farber Cancer Institute investigators will report at a special symposium of the American Association for Cancer Research annual meeting in Washington, April 6-10. The findings (Abstract LB-295) will be released at a press conference on Saturday, April 6, 3:00 p.m. ET, and later at an oral presentation on Tuesday, April 9, 3:35 – 3:50...

WAYNE, N.J. and SOUTH SAN FRANCISCO, Calif., March 25, 2013 /PRNewswire/ -- Bayer HealthCare and Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX) announced today that the Ministry of Health, Labor and Welfare (MHLW) in Japan has approved Stivarga(®) (regorafenib) tablets for the treatment of patients with metastatic colorectal cancer (mCRC). In September 2012, Stivarga was approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with mCRC who have been...

Stivarga(®) (Regorafenib tablets) demonstrated extended overall survival in patients with Metastatic Colorectal Cancer whose disease progressed after previous treatments TORONTO, March 25, 2013 /CNW/ - Bayer Inc. announced today the Health Canada approval of Stivarga (regorafenib tablets), indicated for the treatment of patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-based chemotherapy, oxaliplatin, irinotecan, an...

Markers such as CA9, CD31, CD34 and VEGFR1/2 in the primary tumors might serve as predictors of a good response to a sunitinib treatment in patients with metastatic clear cell renal cell carcinoma (ccRCC), according to a new study to be presented at the 28th Annual EAU Congress currently on-going in Milan. "The inactivation of the von Hippel-Lindau gene (VHL) is a common event in ccRCC and finally leads to the induction of HIF1α target genes such as CA9 and VEGF," write the authors....

WAYNE, N.J. and SOUTH SAN FRANCISCO, Calif., Feb. 25, 2013 /PRNewswire/ -- Intended for U.S. Media Only -- Bayer HealthCare and Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX) announced today that the U.S. Food and Drug Administration (FDA) approved Bayer's Stivarga(®) (regorafenib) tablets to treat patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.(1 )Stivarga...

DURHAM, N.C., Jan. 15, 2013 /PRNewswire/ -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis(TM) technology platform, announced that the first patients have been enrolled in the ADAPT Phase 3 clinical study for AGS-003, its most advanced product candidate. AGS-003 is an investigational, fully personalized, dendritic-cell...

-- First publication of the global Phase III CORRECT and GRID study data of the oral multi-kinase inhibitor regorafenib TORONTO, Nov. 27, 2012 /CNW/ - Bayer HealthCare today announced that the results of two pivotal Phase III studies for regorafenib were published online in the journal The Lancet ahead of a future print publication. Data from the CORRECT (Metastatic Colorectal cancer treated with regorafenib or placebo after failure of standard therapy)...

A new targeted drug demonstrated its ability to control metastatic gastrointestinal stromal tumor, an uncommon and life-threatening form of sarcoma, after the disease had become resistant to all existing therapies, report investigators at Dana-Farber Cancer Institute who led the worldwide clinical trial. The treatment of gastrointestinal stromal tumor, or GIST, even in its advanced metastatic stage, has been dramatically improved with two oral targeted drugs – imatinib (Gleevec) and...